BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid,Seock-Ah Im,Anne C Armstrong,Yeon Hee Park,Wei Pang Chung,Zbigniew Nowecki,Simon Lord,Piotr J. Wysocki,Yen-Shen Lu,Hannah Dry,Vatsala Karwe,Ross Stewart,P. Herbolsheimer,Ana Tablante Nunes,Kyung Hae Jung

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

2021

Peter Schmid
Seock-Ah Im
Anne C Armstrong
Yeon Hee Park
Wei Pang Chung
Zbigniew Nowecki
Simon Lord
Piotr J. Wysocki
Yen-Shen Lu
Hannah Dry
Vatsala Karwe
Ross Stewart
P. Herbolsheimer
Ana Tablante Nunes
Kyung Hae Jung

1023Background: Chemotherapy with immune checkpoint inhibitors can improve outcomes vs chemotherapy alone in patients (pts) with metastatic TNBC; however, many still have poor clinical outcomes. BE...

Keywords:

in patient
Durvalumab
locally advanced
Triple-negative breast cancer
Medicine
Internal medicine
Chemotherapy
Oncology
Paclitaxel
Trastuzumab
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations